Latest Revenue News

Page 18 of 912
Eminence Minerals has cut its FY2026 loss and raised its pro forma cash position to about A$5.4 million after selling the Mata da Corda titanium project. The portfolio is now centred on Hamersley iron ore and Brazilian rare earth exploration, but heritage litigation, ungranted tenure and future funding needs remain material constraints.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Green Technology Metals has cleared the environmental assessment for its Seymour lithium project, while a A$15.9 million capital raising leaves the company better placed to complete its definitive feasibility study. The next test is whether permitting, financing and Indigenous agreements can convert that progress into a Final Investment Decision in FY27.
Maxwell Dee
Maxwell Dee
29 Sept 2026
VBX has expanded the Wuudagu Bauxite Project’s resource to 143.2 million tonnes, but its FY26 accounts expose acute funding pressure, with just $301,208 in cash and an auditor warning of material uncertainty over going concern. The definitive feasibility study has been pushed into the first quarter of 2027 while the company relies on fresh equity, related-party funding and prospective strategic partners.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Duxton Farms has warned of a material uncertainty around its ability to continue as a going concern after a merger-driven loss, sharply higher borrowings and heavy cash outflows. The agricultural group is relying on asset sales, cost reductions and fresh funding while it tries to shift from mature broadacre assets into longer-dated development projects.
Ada Torres
Ada Torres
29 Sept 2026
Resource Base Limited (ASX:RBX) reduced its FY2026 loss, but ended the year with only $140,776 in cash and an auditor warning of material uncertainty over its ability to continue as a going concern. The company is relying on fresh capital to advance early-stage titanium targets in South Australia.
Maxwell Dee
Maxwell Dee
29 Sept 2026
AdNeo Limited (ASX: AD1) nearly doubled operating revenue in FY26 and delivered its first full-year operating cash inflow, marking a sharp turnaround after the Learnt Global acquisition. The recovery remains incomplete, with a $3.97 million loss, significant current liabilities and an auditor-drawn material uncertainty over going concern.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Unico Silver has more than tripled its reported silver-equivalent resource base across Joaquin and Cerro Leon, ending FY26 with A$55.1 million in cash and a maiden Joaquin Pre-Feasibility Study ahead. The next stage will test whether geological scale can become an economically viable project.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Hot Chili’s La Verde copper-gold discovery has expanded rapidly enough to become a cornerstone of the Costa Fuego project, while new funding gives the company room to pursue the next studies and permits. The key test now is whether drilling can translate into a maiden resource and a credible development case.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Juno Minerals has completed the sale of its Mount Mason project for A$6 million plus a 2% production royalty, but the buyer has pushed development into 2027. The company is now concentrating on finding a partner for its large, capital-intensive Mount Ida magnetite project.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Audalia Resources has outlined a 24.2 million tonne Medcalf resource, a maiden 11.77 million tonne probable ore reserve and study economics of up to $227 million in NPV. But the ASX-listed developer also reported a $1.31 million loss, only $720,861 in cash and an auditor warning over its ability to continue as a going concern.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Australian Gold and Copper expanded its exploration footprint and advanced major targets during FY2026, but the campaign came with a larger loss and a sharp reduction in cash. The company now has a 38.5Moz silver-equivalent Achilles resource, a newly acquired Junee gold portfolio and further funding demands ahead.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
Victor Sage
Victor Sage
29 Sept 2026

Browse the archive

Full archive